Literature DB >> 30992220

Safety of Intratracheal Administration of Human Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low Birth Weight Preterm Infants.

Steven B Powell1, Jean M Silvestri2.   

Abstract

In a phase 1 dose-escalation trial at 2 dosing levels, we assessed the safety of intratracheal administration of a single-dose of human umbilical cord blood-derived mesenchymal stromal cells in 12 extremely low birth weight infants <28 weeks of gestation and <1000 g at birth at 5-14 days of life. The treatment was well tolerated and appears to be safe and feasible, and warrants a larger randomized-controlled blinded study. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02381366.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  BPD; MSCs; NICU; chronic lung disease; neonatal; neonatal intensive care unit; newborn; prematurity; stem cells

Mesh：

Year:  2019        PMID： 30992220     DOI： 10.1016/j.jpeds.2019.02.029

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  27 in total

1.  Safety and feasibility of umbilical cord blood collection from preterm neonates after delayed cord clamping for the use of improving preterm complications.

Authors:  Zhuxiao Ren; Fang Xu; Jianlan Wang; Zhicheng Zhong; Wei Wei; Jiying Wen; Qi Wang; Liu Guocheng; Jie Yang
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 2.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

3.  Mesenchymal stem cell therapy in perinatal arterial ischemic stroke: systematic review of preclinical studies.

Authors:  Verena Lehnerer; Anna Roidl; Olga Romantsik; Raphael Guzman; Sven Wellmann; Matteo Bruschettini
Journal:  Pediatr Res       Date:  2022-07-29       Impact factor: 3.953

Review 4.  Bronchopulmonary Dysplasia: Then, Now, and Next.

Authors:  Michael C Tracy; David N Cornfield
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-09       Impact factor: 0.885

Review 5.  Stem cell-based therapy for human diseases.

Authors:  Duc M Hoang; Phuong T Pham; Trung Q Bach; Anh T L Ngo; Quyen T Nguyen; Trang T K Phan; Giang H Nguyen; Phuong T T Le; Van T Hoang; Nicholas R Forsyth; Michael Heke; Liem Thanh Nguyen
Journal:  Signal Transduct Target Ther       Date:  2022-08-06

Review 6.  Early diagnosis and targeted approaches to pulmonary vascular disease in bronchopulmonary dysplasia.

Authors:  Catheline Hocq; Laetitia Vanhoutte; Axelle Guilloteau; Anna Claudia Massolo; Bénédicte Van Grambezen; Kate Carkeek; Fiammetta Piersigilli; Olivier Danhaive
Journal:  Pediatr Res       Date:  2021-03-05       Impact factor: 3.756

Review 7.  Application Prospects of Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia and the Challenges Encountered.

Authors:  Yajie Tong; Jingye Zuo; Dongmei Yue
Journal:  Biomed Res Int       Date:  2021-05-03       Impact factor: 3.411

Review 8.  Benefits and obstacles to cell therapy in neonates: The INCuBAToR (Innovative Neonatal Cellular Therapy for Bronchopulmonary Dysplasia: Accelerating Translation of Research).

Authors:  Bernard Thébaud; Manoj Lalu; Laurent Renesme; Sasha van Katwyk; Justin Presseau; Kednapa Thavorn; Kelly D Cobey; Brian Hutton; David Moher; Roger F Soll; Dean Fergusson
Journal:  Stem Cells Transl Med       Date:  2021-02-11       Impact factor: 6.940

Review 9.  Hyperoxia-induced bronchopulmonary dysplasia: better models for better therapies.

Authors:  Kiersten Giusto; Heather Wanczyk; Todd Jensen; Christine Finck
Journal:  Dis Model Mech       Date:  2021-02-23       Impact factor: 5.758

10.  Soluble PTX3 of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Attenuates Hyperoxic Lung Injury by Activating Macrophage Polarization in Neonatal Rat Model.

Authors:  Miyeon Kim; Ji Hye Kwon; Yun Kyung Bae; Gee-Hye Kim; Soyoun Um; Jueun Ha; Soo Jin Choi; Wonil Oh; Hye Jin Jin
Journal:  Stem Cells Int       Date:  2020-01-23       Impact factor: 5.443
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.